Tocilizumab, Remdesivir, Favipiravir, and Dexamethasone Repurposed for COVID-19 : a Comprehensive Clinical and Pharmacovigilant Reassessment

© The Author(s), under exclusive licence to Springer Nature Switzerland AG part of Springer Nature 2021..

In this manuscript, we discuss the expectations versus the real-world results of four repurposed COVID-19 drugs: tocilizumab, remdesivir, favipiravir, and dexamethasone from a clinical and pharmacovigilant point of view. We suggest that though the results of two-phase III double-blind clinical trials have been less than expected, tocilizumab has a real remaining potential to treat selected critical cases of COVID-19 beyond clinical trials until more data are revealed. On the contrary, remdesivir, though its FDA approval, and favipiravir are least likely to benefit COVID-19 patients. Moreover, we recommend that the RECOVERY dexamethasone should only be considered for critical hospitalized COVID-19 patients and we urge physicians in developing countries to avoid using it in mild-moderate COVID-19 cases. Finally, we recommend considering a personalized risk-benefit ratio before a decision is made using any of these drugs.

Media Type:

Electronic Article

Year of Publication:

2021

Contained In:

SN comprehensive clinical medicine - (19.02.2021), p. 1-5

Language:

English

Contributors:

Kelleni, Mina T

Links:

Volltext

Keywords:

COVID-19
Dexamethasone
Favipiravir
Journal Article
Remdesivir
Tocilizumab

Notes:

Date Revised 03.03.2021

published: Print-Electronic

Citation Status Publisher

Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Physical Description:

Online-Ressource

doi:

10.1007/s42399-021-00824-4

PMID:

33644693

PPN (Catalogue-ID):

NLM32309693X